Codexis, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Alison Moore
- Full Time Employees
- 188
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 200 Penobscot Drive Redwood City CA United States of America 94063
- IPO Date
- Apr 22, 2010
- CIK
- 0001200375
- Website
- codexis.com
- Similar Companies
- Business
- Codexis, Inc. (NASDAQ:CDXS) develops and provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop and enhance novel high-performance enzymes; offers the ECO Synthesis manufacturing platform to enable scaled enzymatic manufacture of RNAi therapeutics including siRNA; provides pharma biocatalysis enzymes that optimize active pharmaceutical ingredient synthesis with greener processes, higher yields and reduced waste; delivers precision enzymes for molecular biology and diagnostic applications with improved fidelity, selectivity and activity; and supplies custom enzyme engineering services across pharmaceuticals, biotherapeutics and industrial biotechnology. The company operates in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia and China, targeting pharmaceutical companies, biopharma developers and diagnostic firms. Founded in 2002 and headquartered in Redwood City, California, Codexis focuses on sustainable manufacturing solutions for small molecule pharmaceuticals and nucleic acid synthesis. In recent developments, Codexis signed a $37.8 million Supply Assurance Agreement with Merck, announced organizational changes to streamline operations and reduce expenses, leased a GMP manufacturing facility to support scaled production, and entered an evaluation agreement with Nitto Denko Avecia to explore ECO Synthesis for therapeutic siRNA manufacturing; it also finalized an asset purchase agreement with Crosswalk Therapeutics in 2024 for investigational Fabry and Pompe disease gene therapy assets, monetizing non-core programs following a strategic shift.
Codexis, Inc. (CDXS) Q1 2026 Earnings Call Transcript
Codexis (CDXS) Reports Q1 Loss, Beats Revenue Estimates
Codexis Reports First Quarter 2026 Financial Results
Codexis (CDXS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Codexis to share RNA manufacturing advances at TIDES USA
Codexis Posts Strong Q4, Eyes siRNA Market With ECO Synthesis Platform
Why Did Codexis (CDXS) Stock Soar Nearly 38% After Hours?
Codexis, Inc. (CDXS) Q4 2025 Earnings Call Transcript
Codexis (CDXS) Beats Q4 Earnings and Revenue Estimates
Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Codexis Targets 2026 Inflection as CEO Touts ECO Synthesis Push in RNA Manufacturing at TD Cowen Conf
Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis® Manufacturing Platform
Codexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11
Codexis Achieves ISO 9001:2015 Certification
Codexis, Inc. $CDXS Shares Sold by Federated Hermes Inc.
Codexis Expands Reach of the ECO Synthesis® Manufacturing Platform through a Signed Evaluation Agreement with Axolabs for Oligonucleotide Therapeutics
Down 30% in 4 Weeks, Here's Why You Should You Buy the Dip in Codexis (CDXS)
Codexis Announces Signing of Lease for GMP Manufacturing Facility
Codexis, Inc. (CDXS) Q3 2025 Earnings Call Transcript
Codexis (CDXS) Reports Q3 Loss, Misses Revenue Estimates